RxDoctor Payments Data

Roan Forgie

Psychiatric/Mental Health · Smithtown, NYNPI 1578744314

Payments from drug & device makers

$4,753in general payments, 2019–2025

Across 158 payments — averaging $30.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • E.r. Squibb & Sons, L.L.C.$815
  • Otsuka America Pharmaceutical, Inc.$772
  • Neurocrine Biosciences, Inc.$728
  • Alkermes, Inc.$441
  • Axsome Therapeutics, Inc.$357
  • plus $610 from 6 others

What the payments were for

  • Food & beverage$4,63497%
  • Education$1193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,753 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$109,409
Medicare patients
213
Services billed
1,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate28$299,760
Invega SustennaPaliperidone Palmitate54$115,056
Abilify MaintenaAripiprazole37$99,047
AustedoDeutetrabenazine14$71,100
VraylarCariprazine Hcl28$43,460
RexultiBrexpiprazole26$39,893
Risperdal ConstaRisperidone Microspheres24$37,344
LybalviOlanzapine/Samidorphan Malate17$27,875
Divalproex Sodium248$6,420
Clozapine72$6,209
Aripiprazole151$5,834
Fluphenazine Hcl35$5,316
Divalproex Sodium ErDivalproex Sodium59$4,994
Trazodone Hcl265$4,417
Haloperidol96$4,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$728$299,76028 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$27$152,40078 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$772$138,94163 claims
Teva Pharmaceuticals USA, Inc.Austedo$329$71,10014 claims
AbbVieVraylar$1,029$43,46028 claims
Alkermes, Inc.Lybalvi$441$27,87517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →